20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 57,001 shares, a growth of 405.8% from the October 15th total of 11,270 shares. Based on an average trading volume of 160,271 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.6% of the shares of the company are short sold.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of 20/20 Biolabs in a report on Friday, October 30th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.00.
Get Our Latest Stock Report on 20/20 Biolabs
20/20 Biolabs Stock Down 1.4%
AIDX stock traded down $0.00 during trading on Friday, hitting $0.20. The company had a trading volume of 38,164 shares, compared to its average volume of 396,397. The firm has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.95. The stock has a market cap of $2.69 million and a price-to-earnings ratio of -0.37. 20/20 Biolabs has a 12 month low of $0.18 and a 12 month high of $50.00.
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.26) EPS for the quarter. The company had revenue of $0.73 million during the quarter.
About 20/20 Biolabs
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Featured Articles
- Five stocks we like better than 20/20 Biolabs
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
